Korea’s drug safety watchdog said on January 5 that it has given Green Cross Corp. the green light to market Greenflu-S, a vaccine with adjuvant.
The final decision came after consultation with the Central Pharmaceutical Deliberation Committee last December.
Last September, under a deal with Norvatis AG, Green Cross purchased the substance, named MF59, that will allow it to produce 20 mil...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.